Bli medlem
Bli medlem

Du är här


PCI Biotech Holding: PCI Biotech to present at BioTrinity 2014

Oslo, May 12 2014 - PCI Biotech will be presenting at BioTrinity 2014

About BioTrinity 2014 (12-14 May 2014, Novotel London West, UK)
BioTrinity 2014 builds on its established reputation as the largest UK-focused
biopartnering and investment conference, the powerhouse of partnering which
brings together a critical mass of active investors, global pharma and
innovative biotech and medtech companies. The full two-day conference program
features a showcase of the best emerging and clinical stage companies from
across Europe.

The presentation will be held 13 May local time 14:30 and the company will be
represented by Mr. Gaël L'Hévéder, CBDO.

About PCI Biotech
PCI Biotech is a Norwegian biopharmaceutical company developing a novel light
directed treatment system based on its patented photochemical internalisation
(PCI) technology. Originating from world leading research at the Norwegian
Radium Hospital, the PCI method involves first injecting the photosensitiser
Amphinex® and thereafter the therapeutic drug to be specifically delivered to
the diseased cells. When the diseased cells are illuminated the cells'
endosomes are ruptured to allow successful intracellular delivery of the

PCI can enhance the delivery of all molecules taken into the cell by
endocytosis. This includes most types of macromolecules, drugs carried by
antibodies or nanoparticles, as well as some small molecule drugs.

The PCI technology is also a versatile and innovative vaccination platform,
which may specifically increase the cytotoxic T-cell response of vaccines.
This is particularly important in therapeutic vaccination, when the immune
system needs to recognise and destroy diseased cells (e.g. virus infected
cells and cancer).

PCI Biotech follows a strategy to create value by improving the effect both of
existing cancer drugs and by realizing the large potential in new
therapeutics, including therapeutic vaccines.

For more information
For further information, please contact

Ronny Skuggedal, CFO

Mobile: +47 9400 5757

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: PCI Biotech Holding via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.